Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00064857
Recruitment Status : Completed
First Posted : July 16, 2003
Last Update Posted : April 22, 2008
Information provided by:
National Center for Complementary and Integrative Health (NCCIH)

July 14, 2003
July 16, 2003
April 22, 2008
August 2003
August 2007   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00064857 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors
Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors
The goal of this study is to evaluate the effectiveness of a standardized botanical extract of Pycnogenol as a treatment for stable arm lymphedema in breast cancer survivors.
Lymphedema of the arm affects the function and self-image of approximately 600,000 of the 2 million breast cancer survivors in the United States. Chronic lymphedema can lead to recurrent infections and permanent swelling, in some cases impairing function. Although various methods of massage and the use of non-elastic compression "sleeves" have been shown to decrease the severity of lymphedema, these methods of physical therapy are limited in terms of patient acceptance, compliance, and by the availability of trained therapists. There is presently no pharmacologic treatment that has proven effective in treating or preventing the development of lymphedema in women treated for breast cancer. This is a double-blind, placebo-controlled trial of an extract of the bark of the French maritime pine tree (Pycnogenol(r)) as a treatment for arm lymphedema in breast cancer survivors. Pycnogenol(r) is widely used in Europe for lymphedema of the leg and varicose veins, and is thought to act by several mechanisms including vascular permeability and vascular constriction. The development of such a therapeutic approach would therefore constitute a major breakthrough in the treatment of this common symptom of breast cancer lymphedema. Bioelectric impedance is a painless, quick, and easily-performed method of estimating the extracellular and total water volume of the body or segment, such as the arm. We will compare the correlation of both a single- and a multiple-frequency bioelectric impedance instrument in measuring change in arm volume to a standard assessment using water displacement. We expect that bioelectric impedance will prove faster and more sensitive to changes in extracellular water (lymphedema) than the water displacement method. We also propose to use a small oral dose of midazolam and single blood sampling to screen for effects of Pycnogenol(r) on the activity of the common drug metabolizing enzyme CYP3A4. For those subjects who are already receiving digoxin, we will use digoxin urine excretion to screen for effects of the botanical upon the activity of P-glycoprotein. Finally, we will continue the evaluation of a new questionnaire of lymphedema symptoms presently being tested as a tool for assessing the severity and improvement of symptoms with treatment. In summary, the successful completion of this research can be expected to provide an alternative therapy and new instruments for treating and measuring lymphedema.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Lymphedema
  • Breast
  • Cancer
Drug: Pycnogenol
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2007
August 2007   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Unilateral (ipsilateral to breast cancer resection side) lymphedema of the upper extremity.
  • Extravascular water ration of > 1.07/1 between affected vs. normal arm using multiple frequency bioelectric impedence
  • Patient is > 2months from last surgical or radiation treatment to the affected axilla
  • Renal and hepatic function:

Creatinine clearance > 50ml/min, total bili <2 mg/dl, transaminases <1.5 x ULN

  • Patient not pregnant or breastfeeding. Use of barrier contraception if sexually active.
  • ECOG performance of 0-2
  • Patient not allergic to pycnogenol

Exclusion criteria:

  • Patients treated with their first course of chemotherapy or radiation
  • Chemotherapy or radiation to axillary lymph node will exclude patients for 8 weeks following treatment
  • Patients with more than one episode of arm cellulitis, venous clot, or woody fibrosis of the affected arm. Antibiotics used to treat cellulitis must be completed at least 4 weeks prior to initial screening
  • Patients with a defibrillator Midazolam study only: Patients requiring or benefiting from supplemental oxygen, patients allergic to cherries
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R21AT001724-01( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
National Center for Complementary and Integrative Health (NCCIH)
Not Provided
Study Chair: James F. Cleary, M.B.B.S. University of Wisconsin, Madison
National Center for Complementary and Integrative Health (NCCIH)
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP